1
|
Obr A, Klener P, Furst T, Kriegova E, Zemanova Z, Urbankova H, Jirkuvova A, Petrackova A, Malarikova D, Forsterova K, Cudova B, Sedlarikova L, Berkova A, Kasalova N, Papajik T, Trneny M. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol 2020; 191:e103-e106. [PMID: 32862455 DOI: 10.1111/bjh.17063] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Ales Obr
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Pavel Klener
- First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.,Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Tomas Furst
- Department of Mathematical Analysis and Application of Mathematics, Faculty of Science, Palacky University, Olomouc, Czech Republic
| | - Eva Kriegova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Zuzana Zemanova
- Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Prague, Czech Republic
| | - Helena Urbankova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Andrea Jirkuvova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Anna Petrackova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Diana Malarikova
- First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.,Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Kristina Forsterova
- First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Barbora Cudova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Lenka Sedlarikova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Adela Berkova
- Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Prague, Czech Republic
| | - Nela Kasalova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Tomas Papajik
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Marek Trneny
- First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|
2
|
Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma. Clin Cancer Res 2019; 25:4455-4465. [DOI: 10.1158/1078-0432.ccr-18-3275] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Revised: 01/30/2019] [Accepted: 04/16/2019] [Indexed: 11/16/2022]
|
3
|
Sarova I, Brezinova J, Zemanova Z, Ransdorfova S, Svobodova K, Izakova S, Pavlistova L, Lizcova L, Berkova A, Skipalova K, Hodanova L, Salek C, Jonasova A, Michalova K. High frequency of dicentric chromosomes detected by multi-centromeric FISH in patients with acute myeloid leukemia and complex karyotype. Leuk Res 2018; 68:85-89. [PMID: 29574397 DOI: 10.1016/j.leukres.2018.03.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Revised: 03/13/2018] [Accepted: 03/18/2018] [Indexed: 11/17/2022]
Abstract
Dicentric chromosomes (DCs) are considered markers of cancer in various malignancies. However, they can be overlooked when conventional analysis or multicolor fluorescence in situ hybridization (mFISH) is used to detect complex karyotypes. We analyzed the karyotypes of 114 patients with acute myeloid leukemia (AML) and complex karyotypes and verified the presence of monosomies by FISH using multi-centromeric probes. Monosomy was detected in 63% of patients by G-banding/mFISH and confirmed in 55% of patients by centromeric FISH. FISH analysis indicated a high frequency of DCs that were previously considered monosomies. In some cases, it was apparent that the derivative monocentric chromosome was a primary DC. DCs were formed mostly by chromosomes 17 and 20. In conclusion, chromosome loss and unbalanced translocation suggest the presence of a hidden DC or its previous existence. DCs undergo several stabilizing changes and can induce other chromosomal aberrations and/or the formation of new DCs. This can result in the clonal evolution of abnormal cells, which is considered an independent prognostic marker of an unfavorable disease course and short survival.
Collapse
Affiliation(s)
- Iveta Sarova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic; Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
| | - Jana Brezinova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic
| | - Zuzana Zemanova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Sarka Ransdorfova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic
| | - Karla Svobodova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Silvia Izakova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Lenka Pavlistova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Libuse Lizcova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Adela Berkova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Karolina Skipalova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Lucie Hodanova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Cyril Salek
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic
| | - Anna Jonasova
- 1st Department of Internal Medicine of General University Hospital and 1st Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Kyra Michalova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic; Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| |
Collapse
|
4
|
Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematol Oncol 2017; 36:110-115. [DOI: 10.1002/hon.2483] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2017] [Revised: 09/26/2017] [Accepted: 09/27/2017] [Indexed: 11/07/2022]
Affiliation(s)
- Pavel Klener
- First Medical Department; Charles University General Hospital in Prague; Prague Czech Republic
- Institute of Pathological Physiology, First Faculty of Medicine; Charles University in Prague; Prague Czech Republic
| | - Eva Fronkova
- CLIP, Deparment of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital in Motol; Prague Czech Republic
| | - David Belada
- Fourth Department of Internal Medicine-Hematology; Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Králové Czech Republic
| | - Kristina Forsterova
- First Medical Department; Charles University General Hospital in Prague; Prague Czech Republic
| | - Robert Pytlik
- First Medical Department; Charles University General Hospital in Prague; Prague Czech Republic
| | - Marketa Kalinova
- Department of Pathology and Molecular Medicine; Charles University Hospital in Motol, Prague, and Second Faculty of Medicine; Prague Czech Republic
| | - Martin Simkovic
- Fourth Department of Internal Medicine-Hematology; Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Králové Czech Republic
| | - David Salek
- Department of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - Heidi Mocikova
- Department of Internal Medicine and Haematology; Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University; Prague Czech Republic
| | - Vit Prochazka
- Department of Hemato-Oncology; Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - Petra Blahovcova
- First Medical Department; Charles University General Hospital in Prague; Prague Czech Republic
| | - Andrea Janikova
- Department of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - Jana Markova
- Department of Internal Medicine and Haematology; Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University; Prague Czech Republic
| | - Ales Obr
- Department of Hemato-Oncology; Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - Adela Berkova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics; First Faculty of Medicine, Charles University; Prague Czech Republic
| | - Jozef Kubinyi
- Institute of Nuclear Medicine; Charles University General Hospital in Prague; Prague Czech Republic
| | - Martina Vaskova
- CLIP, Deparment of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital in Motol; Prague Czech Republic
| | - Ester Mejstrikova
- CLIP, Deparment of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital in Motol; Prague Czech Republic
| | - Vit Campr
- Department of Pathology and Molecular Medicine; Charles University Hospital in Motol, Prague, and Second Faculty of Medicine; Prague Czech Republic
| | - Radek Jaksa
- Institute of Pathology; Charles University General Hospital Prague; Prague Czech Republic
| | - Roman Kodet
- Department of Pathology and Molecular Medicine; Charles University Hospital in Motol, Prague, and Second Faculty of Medicine; Prague Czech Republic
| | - Kyra Michalova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics; First Faculty of Medicine, Charles University; Prague Czech Republic
| | - Jan Trka
- CLIP, Deparment of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital in Motol; Prague Czech Republic
| | - Marek Trneny
- First Medical Department; Charles University General Hospital in Prague; Prague Czech Republic
| |
Collapse
|
5
|
Vargova K, Pesta M, Obrtlikova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, Trneny M, Stopka T. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J 2017; 7:e585. [PMID: 28731457 PMCID: PMC5549255 DOI: 10.1038/bcj.2017.63] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Affiliation(s)
- K Vargova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - M Pesta
- Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
| | - P Obrtlikova
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - N Dusilkova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.,Department Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - L Minarik
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic.,Department Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - J Vargova
- Department Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - A Berkova
- Department of Cytogenetics, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - Z Zemanova
- Department of Cytogenetics, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - K Michalova
- Department of Cytogenetics, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - M Spacek
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - M Trneny
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - T Stopka
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic.,Department Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|
6
|
Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcová P, Janikova A, Markova J, Obr A, Berkova A, Vaskova M, Mejstrikova E, Campr V, Kubinyi J, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M. R-CHOP/R-HDAC AND RITUXIMAB MAINTENANCE RESULTS IN HIGH COMPLETE REMISSION RATE, MINIMAL RESIDUAL DISEASE NEGATIVITY, AND EXCELLENT SURVIVAL IN ELDERLY MCL PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Klener
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - E. Fronkova
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - D. Belada
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - K. Forsterova
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - R. Pytlik
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - M. Kalinova
- Institute of Pathology and Molecular Medicine; Charles University Hospital in Motol and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - M. Simkovic
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - D. Salek
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - H. Mocikova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - V. Prochazka
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - P. Blahovcová
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - A. Janikova
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - J. Markova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - A. Obr
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - A. Berkova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - M. Vaskova
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - E. Mejstrikova
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - V. Campr
- Institute of Pathology and Molecular Medicine; Charles University Hospital in Motol and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - J. Kubinyi
- Institute of nuclear medicine; Charles University General Hospital in Prague; Prague Czech Republic
| | - R. Jaksa
- Institute of Pathology; Charles University Hospital and First Faculty of Medicine, Prague; Prague Czech Republic
| | - R. Kodet
- Institute of Pathology and Molecular Medicine; Charles University Hospital in Motol and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - K. Michalova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - J. Trka
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - M. Trneny
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| |
Collapse
|
7
|
Zemanova Z, Michalova K, Brezinova J, Svobodova K, Lhotska H, Sarova I, Lizcova L, Izakova S, Ransdorfova S, Pavlistova L, Berkova A, Skipalova K, Belickova M, Siskova M, Neuwirtova R, Cermak J, Stopka T, Jonasova A. Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5Q). Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30203-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Klener P, Fronkova E, Berkova A, Jaksa R, Lhotska H, Forsterova K, Soukup J, Kulvait V, Vargova J, Fiser K, Prukova D, Alam M, Calvin Lenyeletse Maswabi B, Michalova K, Zemanova Z, Jancuskova T, Pekova S, Trneny M. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years. Int J Cancer 2016; 139:2252-60. [DOI: 10.1002/ijc.30263] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Revised: 05/18/2016] [Accepted: 06/30/2016] [Indexed: 01/06/2023]
Affiliation(s)
- Pavel Klener
- Department of Hematology; Charles University General Hospital Prague; Prague Czech Republic
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - Eva Fronkova
- Childhood Leukemia Investigation Prague (CLIP), Faculty Hospital Motol Prague; Prague Czech Republic
| | - Adela Berkova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - Radek Jaksa
- Department of Pathology; Charles University General Hospital Prague; Prague Czech Republic
| | - Halka Lhotska
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - Kristina Forsterova
- Department of Hematology; Charles University General Hospital Prague; Prague Czech Republic
| | - Jan Soukup
- Department of Pathology and Molecular Medicine; Second Faculty of Medicine, Faculty Hospital Motol Prague; Prague Czech Republic
| | - Vojtech Kulvait
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - Jarmila Vargova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - Karel Fiser
- Childhood Leukemia Investigation Prague (CLIP), Faculty Hospital Motol Prague; Prague Czech Republic
| | - Dana Prukova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - Mahmudul Alam
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | | | - Kyra Michalova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - Zuzana Zemanova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | | | - Sona Pekova
- Synlab Genetics, Department of Cytogenetics; Prague Czech Republic
| | - Marek Trneny
- Department of Hematology; Charles University General Hospital Prague; Prague Czech Republic
| |
Collapse
|
9
|
Mocikova H, Pytlik R, Sykorova A, Janikova A, Prochazka V, Vokurka S, Berkova A, Belada D, Campr V, Buresova L, Trneny M. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. Leuk Lymphoma 2016; 57:2777-2783. [PMID: 27087066 DOI: 10.3109/10428194.2016.1167203] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We have investigated whether the addition of rituximab to methotrexate, procarbazine, vincristine, radiotherapy and cytarabine was associated with improved outcome of primary central nervous system lymphomas (PCNSL). Of 164 patients, 49 received rituximab. Median age was 63 years, median Karnofsky performance score (KPS) was 60 and median follow-up of living patients was 59.5 months. 1- and 2-year PFS were 49.7 and 37.9%, 1- and 2-year OS were 57.0 and 45.3%. Median progression-free survival (PFS), but not overall survival (OS) was significantly better for patients treated with rituximab (22.9 vs. 10.9 months, p = 0.037). In multivariate analysis, age ≤70 years and KPS ≥90 were predictive for PFS and OS, rituximab was an independent prognostic factor for PFS only. In landmark analyses, rituximab was not found beneficial for long-term survivors and no group particularly benefited from rituximab. In conclusion, addition of rituximab was associated with improved PFS, but not OS in this unselected cohort of PCNSL patients.
Collapse
Affiliation(s)
- Heidi Mocikova
- a Department for Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine , Charles University in Prague , Czech Republic
| | - Robert Pytlik
- b First Medical Department - Clinical Department of Haemato-oncology , First Faculty of Medicine and General Teaching Hospital, Charles University in Prague , Czech Republic
| | - Alice Sykorova
- c Fourth Department of Internal Medicine - Hematology , Charles University Hospital and Faculty of Medicine , Hradec Kralove , Czech Republic
| | - Andrea Janikova
- d Department of Internal Medicine and Hemato-oncology , University Hospital , Brno , Czech Republic
| | - Vit Prochazka
- e Department of Hemato-oncology, Faculty of Medicine and Dentistry , Palacky University and University Hospital Olomouc , Czech Republic
| | - Samuel Vokurka
- f Department of Hemato-oncology , University Hospital , Pilsen , Czech Republic
| | - Adela Berkova
- b First Medical Department - Clinical Department of Haemato-oncology , First Faculty of Medicine and General Teaching Hospital, Charles University in Prague , Czech Republic
| | - David Belada
- c Fourth Department of Internal Medicine - Hematology , Charles University Hospital and Faculty of Medicine , Hradec Kralove , Czech Republic
| | - Vit Campr
- g Institute of Pathology and Molecular Medicine, Second Faculty of Medicine , Charles University in Prague , Czech Republic
| | | | - Marek Trneny
- b First Medical Department - Clinical Department of Haemato-oncology , First Faculty of Medicine and General Teaching Hospital, Charles University in Prague , Czech Republic
| | | |
Collapse
|
10
|
Svobodova K, Zemanova Z, Lhotska H, Novakova M, Podskalska L, Belickova M, Brezinova J, Sarova I, Izakova S, Lizcova L, Berkova A, Siskova M, Jonasova A, Cermak J, Michalova K. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. Leuk Res 2016; 42:7-12. [DOI: 10.1016/j.leukres.2016.01.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Revised: 12/16/2015] [Accepted: 01/21/2016] [Indexed: 01/01/2023]
|
11
|
Sarova I, Brezinova J, Zemanova Z, Ransdorfova S, Izakova S, Svobodova K, Pavlistova L, Berkova A, Cermak J, Jonasova A, Siskova M, Michalova K. Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia. Leuk Res 2016; 43:51-7. [PMID: 26821593 DOI: 10.1016/j.leukres.2016.01.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Revised: 11/11/2015] [Accepted: 01/05/2016] [Indexed: 02/08/2023]
Abstract
Dicentric chromosomes (DCs) have been described in many hematological diseases, including acute myeloid leukemia (AML). They are markers of cancer and induce chromosomal instability, leading to the formation of other chromosomal aberrations and the clonal evolution of pathological cells. Our knowledge of the roles and behavior of human DCs is often derived from studies of induced DCs and cell lines. It is difficult to identify all the DCs in the karyotypes of patients because of the limitations of metaphase cytogenetic methods. The aim of this study was to revise the karyotypes of 20 AML patients in whom DCs were found with conventional G-banding or multicolor fluorescence in situ hybridization (mFISH) with (multi)centromeric probes and to characterize the DCs at the molecular cytogenetic level. FISH analyses confirmed 23 of the 29 expected DCs in 18 of 20 patients and identified 13 others that had not been detected cytogenetically. Fourteen DCs were altered by other chromosomal changes. In conclusion, karyotypes with DCs are usually very complex, and we have shown that they often contain more than one DC, which can be missed with conventional or mFISH methods. Our study indicates an association between number of DCs in karyotype and very short survival of patients.
Collapse
Affiliation(s)
- Iveta Sarova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic; Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
| | - Jana Brezinova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic
| | - Zuzana Zemanova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Sarka Ransdorfova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic
| | - Silvia Izakova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Karla Svobodova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Lenka Pavlistova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Adela Berkova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Jaroslav Cermak
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic
| | - Anna Jonasova
- 1st Department of Internal Medicine of General University Hospital and 1st Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Magda Siskova
- 1st Department of Internal Medicine of General University Hospital and 1st Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| | - Kyra Michalova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic; Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 2, 128 08, Prague 2, Czech Republic
| |
Collapse
|
12
|
Sarova I, Brezinova J, Lhotska H, Berkova A, Ransdorfova S, Zemanova Z, Soukupova J, Michalova K. Jumping-like translocation-a rare chromosomal rearrangement in a patient with Burkitt lymphoma/leukemia. Cancer Genet 2014; 207:221-5. [PMID: 24957271 DOI: 10.1016/j.cancergen.2014.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2013] [Revised: 04/14/2014] [Accepted: 05/01/2014] [Indexed: 11/30/2022]
Abstract
Chromosomal translocations are acquired genetic rearrangements in human cancers. Jumping translocations are rare nonreciprocal rearrangements involving the same donor chromosome segment translocated to two or more recipient chromosomes. In this report, we describe a patient with Burkitt lymphoma/leukemia (BL) and a complex karyotype including a t(2;8)(p12;q24), copy-neutral loss of heterozygosity at 17p13.1-p13.3 and 19q13.1-q13.2, trisomy 20, and two uncommon chromosomal aberrations. The first uncommon aberration was a complex rearrangement of chromosome 15 (probably the consequence of chromothripsis) masked by an apparently balanced reciprocal translocation, t(11;15)(p11.2;q21). The second one was a special type of unbalanced "vice versa" jumping translocation, which involved the same acceptor chromosome arm (13q) and various donor chromosome segments. It is unclear whether both atypical rearrangements are the consequence of the TP53 alteration or whether assumed chromothripsis influenced the development of the jumping-like translocation. However, the presence of the t(11;15)(p11.2;q21) in all pathological cells suggests that it occurred in the early stage of the disease, whereas the jumping-like translocation, as an additional change, subsequently accelerated the progression of the disease.
Collapse
Affiliation(s)
- Iveta Sarova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic.
| | - Jana Brezinova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | - Halka Lhotska
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic
| | - Adela Berkova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic
| | - Sarka Ransdorfova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | - Zuzana Zemanova
- Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic
| | | | - Kyra Michalova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic
| |
Collapse
|
13
|
Jonasova A, Obrtlikova P, Siskova M, Cmunt E, Berkova A, Karban J, Svackova K, Trneny M. P-202 MDS development risk in CLL patients with prolonged cytopenia after fludarabine, cyclophosphamide and rituximab (FCR) régime. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70249-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Brezinova J, Berkova A, Vcelikova S, Zemanova Z, Izakova S, Sarova I, Cechova H, Tajtlova J, Grosova L, Lizcova L, Malinova E, Zemanova M, Cmunt E, Karban J, Trneny M, Schwarz J, Michalova K. Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia. Neoplasma 2010; 57:215-21. [PMID: 20353271 DOI: 10.4149/neo_2010_03_215] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
UNLABELLED Telomere length was evaluated by terminal repeat fragment method in 66 previously untreated patients with B-chronic lymphocytic leukemia (B-CLL) to ascertain whether telomere shortening was associated with genomic aberrations, immunoglobulin variable heavy chain (IgVH) mutational status, CD38 and ZAP-70 expression, and telomerase activity. Chromosomal aberrations were present in peripheral blood cells of 73% patients (48/66), no difference in telomere length between patients with good and intermediate prognosis according to cytogenetics was found. Association between telomere length and IgVH mutational status, ZAP-70 and CD38 expression was proved as significantly shorter telomeres in patients with unmutated IgVH status (p=0.01) and ZAP-70 positivity (p=0.01) and CD38 positivity (p=0.05) were detected. Telomerase activity was positive in 11 patients out of 21 examined, correlation between telomere length and telomerase activity was found (p=0.05). Telomere length and telomerase activity in combination with other prognostic parameters complete the risk profile of B-CLL patients and might serve for an easy decision on optimal treatment strategy. KEYWORDS B-chronic lymphocytic leukemia, telomere length, telomerase activity, chromosomal aberrations, prognosis.
Collapse
Affiliation(s)
- J Brezinova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Berkova A, Pavlistova L, Babicka L, Houskova L, Tajtlova J, Balazi P, Cmunt E, Schwarz J, Karban J, Trneny M, Brezinova J, Zemanova Z, Michalova K. Combined molecular biological and molecular cytogenetic analysis of genomic changes in 146 patients with B-cell chronic lymphocytic leukemia. Neoplasma 2008; 55:400-408. [PMID: 18665750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Interphase fluorescence in situ hybridization was used to detect common deletions in B-CLL patients as well as trisomy 12 and aberrations of IgH gene complex at 14q32.33 where we evaluated not only translocation-like signal pattern but also deletions. 120 (82%) patients showed genetic changes - del(13)(q14) 95 (62%), deletion of ATM gene 22 (15%), deletion of p53 gene 25 (17%) and trisomy 12 was proved in 18 (12%) cases. IgH rearrangements were detected in 45 (31%), split of the signals in 11 (8%), deletion of 3' segment flanking IgH gene in 5 (3%) and deletions of variable segment in 29 (20%) patients. Although deletions of 3' segment flanking IgH gene complex are supposed to have an adverse prognostic impact and the genetic background of variable segment deletions is believed to be most probably physiological, we assumed a detailed mapping of the 14q32.33 region will be needed to unravel these mysteries.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Chromosome Aberrations
- Chromosomes, Human, Pair 12
- Chromosomes, Human, Pair 13
- Chromosomes, Human, Pair 14
- Cytogenetic Analysis
- Female
- Humans
- Immunoglobulin Heavy Chains/genetics
- In Situ Hybridization, Fluorescence
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Male
- Middle Aged
- Molecular Diagnostic Techniques
- Mutation
- Retrospective Studies
- Survival Analysis
- Trisomy
Collapse
Affiliation(s)
- A Berkova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, Faculty Hospital and First Faculty of Medicine, Charles University in Prague, Praha, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|